Cargando…
Tolvaptan: A Novel Diuretic in Heart Failure Management
Heart failure (HF) is still a major problem worldwide with high morbidity and mortality rates. The recently developed medication for HF is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient. Argini...
Autores principales: | Zulkifli Amin, Hilman, Suridanda Danny, Siska |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, 2006-
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939249/ https://www.ncbi.nlm.nih.gov/pubmed/27403182 |
Ejemplares similares
-
Galectin-3: a novel biomarker for the prognosis of heart failure
por: AMIN, HILMAN ZULKIFLI, et al.
Publicado: (2017) -
Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project
por: Pose, Antonio, et al.
Publicado: (2017) -
Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017) -
Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction
por: Matsue, Yuya, et al.
Publicado: (2017) -
Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
por: Yamamoto, Tomohiko, et al.
Publicado: (2019)